# A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours

> **NCT05397171** · PHASE1,PHASE2 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 17 (actual)

## Conditions studied

- Urinary Bladder Neoplasms
- Colorectal Cancer
- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** AZD8853
- **DRUG:** Zirconium-89 crefmirlimab berdoxam

## Key facts

- **NCT ID:** NCT05397171
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-07
- **Primary completion:** 2023-06-06
- **Final completion:** 2023-06-06
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** This study was terminated early as per protocol Section 4.4, based on overall risk-benefit profile observed to date. No safety concerns reported. Only Substudy 1 Part A was started; Parts B \& C were not started. Entire Master Protocol was terminated.
- **Last updated:** 2024-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05397171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05397171, "A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05397171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*